Journal of Practical Hepatology ›› 2020, Vol. 23 ›› Issue (4): 540-543.doi: 10.3969/j.issn.1672-5069.2020.04.022

• Drug-induced liver injury • Previous Articles     Next Articles

Clinical feature of 290 patients with drug-induced liver injury

He Wenchang, Zhang Kegong, Zhao Fanhui, et al   

  1. Department of Infectious Diseases, Second Affiliated Hospital, Air Force Medical University, Xi’an 710038, Shaanxi Province, China
  • Received:2019-07-30 Published:2020-07-15

Abstract: Objective The purpose of this study was to investigate the clinical feature of 290 patients with drug-induced liver injury (DILI). Methods 300 hospitalized patients were admitted in our Department of Infectious Diseases from January 2013 through February 2016, and 290 were diagnosed as DILI by the Roussel Uclaf causality assessment (RUCAM) scale. Results The common agents were traditional Chinese medicine, accounting for 42.8%, antibiotics for 9.3% and anti-tuberculosis medicines for 7.6%; the elevated serum alanine aminotransferase levels was the most obvious manifestation; the underlying diseases were chronic gastritis in 18.6%, the hepatocellular injury type accounted for 54.5% and the moderate DILI accounted for 37.6%; 16 patients 5.5% progressed to liver failure and four died; the total treatment effective rate was 93.8%. Conclusion The RUCAM scale is helpful for the standardization of DILI diagnosis. The traditional Chinese medicines account for the highest proportion of liver injuries in our series, and the hepatocellular damage is the most common type. Most DILI patients have a good clinical prognosis. Attentions should be paid to patients with acute liver failure, which is associated with poor prognosis.

Key words: Drug-induced liver injury, RUCAM scale, Clinical features, Prognosis